恩替卡韦联合前列地尔治疗肝硬化失代偿期并发难治性腹水患者的临床疗效及肝肾功能的影响

Clinical effect of entecavir combined with alprostadil on liver and kidney function in patients with decompensated liver cirrhosis complicated with refractory ascites

目的探讨恩替卡韦联合前列地尔治疗肝硬化失代偿期并发难治性腹水患者的临床疗效及肝肾功能的影响。方法选取2018年1月至2020年12月本院收治的86例肝硬化失代偿期并发难治性腹水患者作为研究对象,按随机数字表法分为参照组和治疗组,每组43例。参照组采用恩替卡韦治疗,治疗组在参照组基础上联合前列地尔治疗,比较两组临床疗效、肝肾功能指标及不良反应发生情况。结果治疗组治疗总有效率高于参照组,差异有统计学意义(P<0.05)。治疗前,两组总胆红素、血肌酐、尿氮素及清蛋白水平比较差异均无统计学意义;治疗后,两组总胆红素、血肌酐及尿氮素水平均低于治疗前,清蛋白水平高于治疗前,且治疗组总胆红素、血肌酐及尿氮素水平均低于参照组,清蛋白水平高于参照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论恩替卡韦联合前列地尔治疗肝硬化失代偿期并发难治性腹水患者的疗效显著,有利于肝肾功能的恢复,可调节腹水,且不增加不良反应发生,值得临床推广应用。

Objective To investigate the clinical effect of entecavir combined with alprostadil on liver and kidney function in patients with decompensated liver cirrhosis complicated with refractory ascites.Methods 86 patients with decompensated liver cirrhosis admitted to our hospital from January 2018 to December 2020 were selected as the research subjects,and they were divided into reference group and treatment group according to the random number table method,with 43 cases in each group.The reference group was treated with entecavir,and the treatment group was combined with alproteadil based on basis of the reference group.The clinical efficacy,liver and renal function indicators and adverse effects were compared between the two groups.Results The total effective rate in treatment of the treatment group was higher than that of the reference group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of total bilirubin,serum creatinine,urea nitrogen and albumin between the two groups;after treatment,the levels of total bilirubin,serum creatinine and urinary nitrogen in the two groups were lower than those before treatment,and the level of albumin was higher than that before treatment,and the levels of total bilirubin,serum creatinine and urinary nitrogen in the treatment group were lower than those in the reference group,and the albumin level was higher than that in the reference group,the differences was statistically significant(P<0.05).There was no significant difference in the incidence of adverse effects between the two groups.Conclusion Entecavir combined with alprostadil has significant clinical efficacy on patients with decompensated liver cirrhosis complicated with refractory ascites,which is conducive to the recovery of liver and kidney function,ascites regulation and no increase in adverse reactions,it is worthy of clinical promotion.